Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000484804 | SCV000572699 | uncertain significance | not provided | 2017-01-30 | criteria provided, single submitter | clinical testing | The S2183G variant in the EYS gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The S2183G variant is observed in 9/2144 (0.4%) alleles from individuals of African background, in the ExAC database (Lek et al., 2016). The S2183G variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is not conserved. In silico analysis predicts this variant likely does not alter the protein structure/function. We interpret S2183G as a variant of uncertain significance. |
Labcorp Genetics |
RCV000484804 | SCV001033274 | likely benign | not provided | 2024-11-19 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004619303 | SCV005112950 | uncertain significance | Inborn genetic diseases | 2024-06-10 | criteria provided, single submitter | clinical testing | The c.6547A>G (p.S2183G) alteration is located in exon 32 (coding exon 29) of the EYS gene. This alteration results from a A to G substitution at nucleotide position 6547, causing the serine (S) at amino acid position 2183 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001272974 | SCV001455488 | uncertain significance | Retinitis pigmentosa 25 | 2019-10-28 | no assertion criteria provided | clinical testing |